NASDAQ : ATTO
Attovia Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 15.19 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 693.44M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Attovia Therapeutics, Inc. (ATTO) reported revenue of 1.80M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 1.80M | 1.35M | |
| Cost of Revenue | 64.26M | 54.15M | 33.86M |
| Gross Profit | -62.46M | -52.80M | -33.86M |
| Selling, General & Admin | 13.59M | 14.36M | 7.69M |
| Operating Expenses | 13.73M | 14.36M | 7.69M |
| Operating Income | -76.19M | -67.16M | -41.55M |
| Interest & Investment Income | 5.93M | 6.63M | 3.44M |
| Other Non Operating Income (Expenses) | -114.00K | -95.00K | -1.69M |
| Pretax Income | -70.38M | -60.63M | -39.80M |
| Net Income | -70.38M | -60.63M | -39.80M |
| Net Income to Common | -70.11M | -60.63M | -39.80M |
| Shares Outstanding (Basic) | 4.12M | 3.95M | 3.53M |
| Shares Outstanding (Diluted) | 4.12M | 3.95M | 3.53M |
| EPS (Basic) | -17.01 | -15.35 | -11.27 |
| EPS (Diluted) | -17.01 | -15.35 | -11.27 |
| Free Cash Flow | -68.22M | -61.51M | -36.81M |
| Free Cash Flow Per Share | -16.55 | -15.57 | -10.42 |
| Operating Margin | -4,232.94% | -4,974.74% | |
| Profit Margin | -3,894.94% | -4,490.89% | |
| Free Cash Flow Margin | -3,790.11% | -4,556.44% | |
| EBITDA | -75.25M | -66.36M | -41.24M |
| D&A For EBITDA | 942.00K | 804.00K | 313.00K |
| EBIT | -76.19M | -67.16M | -41.55M |
| Revenue as Reported | 1.80M | 1.35M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 32.83M | 40.19M | 30.63M |
| Short-Term Investments | 82.30M | 112.08M | 38.69M |
| Cash & Short-Term Investments | 115.13M | 152.27M | 69.32M |
| Other Receivables | 900.00K | 900.00K | 100.00K |
| Receivables | 900.00K | 900.00K | 100.00K |
| Prepaid Expenses | 2.37M | 3.13M | 3.06M |
| Total Current Assets | 118.40M | 156.29M | 72.48M |
| Property, Plant & Equipment | 6.92M | 7.87M | 3.23M |
| Other Long-Term Assets | 3.03M | 1.73M | 1.00M |
| Total Assets | 128.35M | 165.89M | 76.72M |
| Accounts Payable | 6.00M | 3.55M | 4.14M |
| Accrued Expenses | 4.58M | 5.08M | 3.58M |
| Current Portion of Leases | 2.04M | 1.92M | |
| Current Unearned Revenue | 450.00K | ||
| Total Current Liabilities | 12.62M | 11.01M | 7.72M |
| Long-Term Leases | 2.29M | 3.34M | |
| Other Long-Term Liabilities | 678.00K | 755.00K | 6.87M |
| Total Liabilities | 15.58M | 15.10M | 14.59M |
| Common Stock | 1.00K | 4.00K | 4.00K |
| Additional Paid-In Capital | 4.97M | 3.47M | 3.49M |
| Retained Earnings | -150.35M | -111.01M | -50.38M |
| Comprehensive Income & Other | -79.00K | 99.00K | 67.00K |
| Total Common Equity | -145.46M | -107.44M | -46.83M |
| Shareholders' Equity | 112.77M | 150.79M | 62.13M |
| Total Liabilities & Equity | 128.35M | 165.89M | 76.72M |
| Total Debt | 4.33M | 5.26M | |
| Net Cash (Debt) | 110.81M | 147.01M | 69.32M |
| Net Cash Per Share | 26.88 | 37.22 | 19.63 |
| Filing Date Shares Outstanding | 45.65M | 4.43M | 4.43M |
| Total Common Shares Outstanding | 4.53M | 4.43M | 4.43M |
| Working Capital | 105.79M | 145.29M | 64.76M |
| Book Value Per Share | -32.12 | -24.27 | -10.58 |
| Tangible Book Value | -145.46M | -107.44M | -46.83M |
| Tangible Book Value Per Share | -32.12 | -24.27 | -10.58 |
| Machinery | 4.73M | 4.42M | 1.96M |
| Construction In Progress | 64.00K | 28.00K | 1.57M |
| Leasehold Improvements | 136.00K | 136.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -70.38M | -60.63M | -39.80M |
| Depreciation & Amortization | 942.00K | 804.00K | 313.00K |
| Other Amortization | 393.00K | ||
| Loss (Gain) From Sale of Assets | 1.00K | 7.00K | 7.00K |
| Loss (Gain) From Sale of Investments | -1.77M | -2.66M | -681.00K |
| Stock-Based Compensation | 2.74M | 2.39M | 1.39M |
| Other Operating Activities | 211.00K | 218.00K | 2.20M |
| Change in Accounts Payable | 1.17M | 180.00K | 1.72M |
| Change in Other Net Operating Assets | -348.00K | 96.00K | -181.00K |
| Operating Cash Flow | -67.43M | -59.20M | -35.03M |
| Capital Expenditures | -788.00K | -2.31M | -1.77M |
| Investment in Securities | 60.16M | -71.14M | -38.03M |
| Investing Cash Flow | 59.37M | -73.45M | -39.80M |
| Long-Term Debt Repaid | -171.00K | ||
| Net Debt Issued (Repaid) | -171.00K | ||
| Issuance of Common Stock | 93.00K | 194.00K | 310.00K |
| Other Financing Activities | -1.84M | -376.00K | -19.00K |
| Financing Cash Flow | -1.75M | 142.01M | 82.75M |
| Net Cash Flow | -9.82M | 9.36M | 7.91M |
| Free Cash Flow | -68.22M | -61.51M | -36.81M |
| Free Cash Flow Margin | -3,790.11% | -4,556.44% | |
| Free Cash Flow Per Share | -16.55 | -15.57 | -10.42 |
| Levered Free Cash Flow | -40.21M | ||
| Unlevered Free Cash Flow | -40.21M | ||
| Change in Working Capital | 817.00K | 276.00K | 1.54M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 693.44M | ||
| Enterprise Value | 582.64M | ||
| Debt / Equity Ratio | 0.04 | 0.04 | |
| Net Debt / Equity Ratio | -0.98 | -0.97 | -1.12 |
| Net Debt / EBITDA Ratio | 1.47 | 2.21 | 1.68 |
| Net Debt / FCF Ratio | 1.62 | 2.39 | 1.88 |
| Asset Turnover | 0.01 | ||
| Quick Ratio | 9.20 | 13.92 | 8.99 |
| Current Ratio | 9.39 | 14.20 | 9.39 |
| Return on Equity (ROE) | -56.95% | ||
| Return on Assets (ROA) | -34.60% | ||
| Return on Capital Employed (ROCE) | -65.80% | -43.40% | -60.20% |
| Buyback Yield / Dilution | -11.84% |